Biopharma

Photo

Symeres Acquires DGr Pharma

CRDMO Symeres has acquired DGr Pharma, expanding its capabilities with DGr Pharma’s regulatory and consultancy expertise to provide more comprehensive drug development services.

Photo

Pharma Outlook 2025

The environment for pharma in 2025 is diverse and challenging: New treatment options are being brought to market in ever shorter cycles.

Photo

Amgen Plans $1 Billion Manufacturing Expansion in North Carolina

In a move to expand its global biomanufacturing network, US biopharma Amgen is planning to invest $1 billion to build a second drug substance manufacturing facility at its US site in Holy Springs, North Carolina. This brings the company's total planned investment in Holly Springs to more than $1.5 billion, building on its previously announced $550 million commitment.

Photo

Agilent to Buy Canadian CDMO Biovectra for $925 Million

Santa Clara, CA-based Agilent Technologies has signed a definitive agreement to acquire specialized contract development and manufacturing organization Biovectra from H.I.G. Capital in a move to expand its end-to-end biopharma solutions.

Photo

3M Ramps Up Biopharma Filtration Capabilities

Science and technology group 3M has announced plans to invest $146 million to expand its biopharma filtration capabilities at manufacturing facilities in Europe. The company did not disclose the facilities’ locations.

Photo

FTC Seeks to Block Amgen-Horizon Merger

Calling the deal announced late last year an alarming sign for biopharma, the US Federal Trade Commission (FTC) is seeking to block the closing of Amgen’s proposed $28 billion acquisition of Horizon Therapeutics with a temporary restraining order and preliminary injunction.

Photo

Wacker Buys All of ADL BioPharma from Private Equity

German chemical group Wacker has acquired 100% of ADL Biopharma from private equity investor Kartesia for a price said to exceed €100 million. It now owns the entire 150,000 m2 production site in the northern Spanish city of Léon with fermentation capacity of just under 3,000 cbm (gross volume).

37 more articles

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.